Yakup Ergün· @dr_yakupergun · X·· 1 天前评分70
正文 · 原文
#ESMO26 | FINER – Updated OS
Despite the PFS benefit, ipatasertib + fulvestrant failed to improve OS in HR+/HER2− mBC after CDK4/6i + AI.
ITT: HR 0.97 (p=0.83)
AKT pathway-altered: HR 0.88
38 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA14按 Proffered paper 2: Breast cancer, early and advanced stage 对上
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.org#ESMO26 | FINER In HR+/HER2− mBC, ipatasertib + fulvestrant failed to demonstrate an OS benefit despite improving PFS (26.7 vs 25.8 mo; HR 1.14). No OS benefit was observed in patients with AKT pathway alterations either (HR 1.14)!!! I’m eagerly awaiting the presentation details to better understand why the PFS benefit did not translate into an OS advantage.在 X 查看被引用的帖子
来源：Yakup Ergün · x.com